Article Text

Download PDFPDF
Ablative therapy for liver tumours
  1. E A Dick1,
  2. S D Taylor-Robinson2,
  3. H C Thomas2,
  4. W M W Gedroyc1
  1. 1Department of Interventional Magnetic Resonance Imaging, Imperial College School of Medicine, St Mary's Hospital, London, UK
  2. 2Hepatology Unit, Division of Medicine A, Imperial College School of Medicine, St Mary's Hospital, London, UK
  1. Correspondence to:
    Dr W M W Gedroyc, Department of Interventional Magnetic Resonance Imaging, St Mary's Hospital, Praed St, London W2 1NY, UK;
    w.gedroyc{at}ic.ac.uk.

Abstract

Established ablative therapies for the treatment of primary and secondary liver tumours, including percutaneous ethanol injection, cryotherapy, and radiofrequency ablation, are discussed. Newer techniques such as magnetic resonance imaging guided laser interstitial thermal therapy of liver tumours has produced a median survival rate of 40.8 months after treatment. The merits of this newly emerging technique are discussed, together with future developments, such as focused ultrasound therapy, which holds the promise of non-invasive thermoablation treatment on an outpatient basis.

  • ablative therapy
  • hepatocellular carcinoma
  • hepatic metastases
  • magnetic resonance imaging
  • RFA, radiofrequency ablation
  • PEI, percutaneous ethanol injection
  • LITT, laser interstitial thermal therapy
  • HCC, hepatocellular carcinoma
  • CRC, colorectal carcinoma
  • HBV, hepatitis B virus
  • HCV, hepatitis C virus
  • US, ultrasound
  • CT, computed tomography
  • MRI, magnetic resonance imaging
  • FUS, focused ultrasound
  • Nd:YAG, neodymium yttrium aluminium garnet

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes